Skylands Capital LLC Increases Stock Position in Exact Sciences Co. (NASDAQ:EXAS)

Skylands Capital LLC boosted its position in Exact Sciences Co. (NASDAQ:EXAS) by 2,850.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,800 shares of the medical research company’s stock after purchasing an additional 11,400 shares during the quarter. Skylands Capital LLC’s holdings in Exact Sciences were worth $663,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently modified their holdings of EXAS. Huntington National Bank raised its position in Exact Sciences by 838.1% during the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC bought a new stake in shares of Exact Sciences in the 3rd quarter worth approximately $34,000. Capital Performance Advisors LLP purchased a new stake in shares of Exact Sciences in the 3rd quarter valued at $35,000. Asset Planning Inc purchased a new position in Exact Sciences in the 4th quarter worth $40,000. Finally, Modus Advisors LLC purchased a new stake in Exact Sciences during the fourth quarter valued at about $43,000. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Price Performance

NASDAQ EXAS opened at $49.26 on Monday. The business’s fifty day moving average is $54.91 and its 200 day moving average is $60.04. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. The company has a market capitalization of $9.15 billion, a PE ratio of -8.84 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The company had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. Sell-side analysts predict that Exact Sciences Co. will post -0.58 earnings per share for the current year.

Wall Street Analyst Weigh In

EXAS has been the topic of several recent research reports. TD Cowen raised their price target on Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Barclays cut their price objective on Exact Sciences from $70.00 to $65.00 and set an “overweight” rating on the stock in a research report on Thursday. The Goldman Sachs Group dropped their price target on Exact Sciences from $75.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Sanford C. Bernstein lifted their price target on shares of Exact Sciences from $75.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Finally, Bank of America lowered their target price on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating for the company in a report on Thursday. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, Exact Sciences has an average rating of “Moderate Buy” and an average price target of $72.06.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.